Lasa Supergenerics Limited — Updates, 24-04-2025: Press Release

Lasa Supergenerics Limited has announced the successful expansion of its manufacturing capacity for Albendazole USP, enhancing its ability to meet the rising global demand. This initiative involved strategic debottlenecking of existing infrastructure and the installation of new machinery at their facility, anticipating a 20% growth in total capacity. This expansion, supported by a capital investment of nearly Rs. 100.00 Crore, aims to improve product efficiency and reduce lead times while upholding top-tier quality standards. Dr. Omkar Herlekar, Chairman and Managing Director, expressed enthusiasm for this milestone, highlighting the company's commitment to supporting customers and reinforcing its position as a trusted API supplier in the pharmaceutical industry.